Journey Medical CORP Form 4 insider transactions

Journey Medical Corp's CFO, Joseph Benesch, sold 9,324 shares to cover tax obligations related to vesting restricted stock units.

Director Michael Cooper Pearce of Journey Medical Corp was granted 30,000 restricted stock units on July 19, 2024, under the company's 2015 Stock Plan.

Journey Medical Corp's CFO, Joseph Benesch, sold 4,055 shares of common stock on July 23, 2024, to cover tax obligations related to vesting restricted stock units.

Director Justin Adam Smith received 9,728 restricted stock units from Journey Medical Corp, vesting on July 8, 2025.

Director Neil Herskowitz of Journey Medical Corp reports acquisition of restricted stock units.

Director Miranda Jayne Toledano acquired 9,728 restricted stock units in Journey Medical Corp, vesting on July 8, 2025, according to a Form 4 filing.

Director Lindsay A. Rosenwald acquired 9,728 restricted stock units in Journey Medical Corp on July 8, 2024, vesting fully on July 8, 2025.

Fortress Biotech, a 10% owner of Journey Medical Corp, reports the transfer of 250,000 shares to employees as service grants between May 2022 and May 2023, decreasing its holdings.

Director Lindsay A. Rosenwald purchased 10,000 shares of Journey Medical Corp (DERM) at $3.04 per share on March 25, 2024.

Claude Maraoui, President & CEO of Journey Medical Corp, purchased 10,000 shares of the company's common stock at an average price of $3.479 on March 22, 2024.

Director Justin Adam Smith of Journey Medical Corp purchased 30,000 shares of common stock at $3.47 per share on March 22, 2024.

Director Lindsay A. Rosenwald purchased 20,000 shares of Journey Medical Corp (DERM) at $3.40 per share on March 22, 2024.